SEC Delinquent Invo Bioscience Inc (OTCMKTS:IVOB) Surges Out of Nowhere

The stock of Invo Bioscience Inc (OTCMKTS:IVOB) had been traded in a relatively flat price tunnel since January. Until yesterday, though. Clocking in at $0.45 per share, IVOB jumped 28%, thus hitting a six-month high on a hefty volume of approximately 400 thousand. Was it a one-day wonder or the beginning of something big?

Could be. The company is focused on providing affordable solutions in the field of assisted reproductive technologies with its proprietary INVOCell device being its main driving force. If successfull, the device, along with the accompanying technology, could indeed revolutionize this otherwise sensitive branch of medical science not only nationwide, but also worldwide. The rosy future of the company could easily be sealed had it not been for one simple fact that has more or less created some cause for alarm.

You know what we are getting at. Our alarm bells are ringing because of IVOB‘s practice of having kept its business operations and the results thereof under wraps for more than three years now. Indeed, Invo’s managers filed an NT 10-K on Mar. 30, 2012, thus allowing themselves a fortnight’s grace to put the finishing touches on the 2011 annual report. This extention has obiously proven insufficient because the 10-K in question has yet to see the light of day. What is more, IVOB never bothered to adopt an alternative reporting standard, either. As a result, the ticker is now proudly bearing the STOP sign on the pink sheets and keeping investors in the dark.

As for the INVOCell itself, it seems to be available outside the United States because the FDA has yet to aprove the product candidate for national distribution. The company expects to commence a full-blown trial “as soon as it is financially viable to do so”. Since recent financial records are nowhere to be found out there, the launch fo such a trial could stretch on and on and on, with no green light in sight. That is why, the Oct. 22, 2014 press release issued by the American Society for Reproductive medicine, which deems INVOCell safe and effective, is fairly encouraging. Nevertheless, there is still a long way to go to make sure that IVOB stock is a safe, high-yield investment.